Ping An Securities released a research report on April 24 stating that it gave Jingxin Pharmaceutical (002020.SZ) a recommended rating. The main reasons for the rating include: 1) the company's 24Q1 revenue side resumed relatively rapid growth, and the profit side returned to a long-term growth trajectory; 2) the adjustment of the finished drug sales structure showed initial results, and product profitability was gradually optimized; 3) the company had plenty of cash on hand, and multiple mental nerves continued to advance in the research pipeline. (Mainichi Keizai Shimbun)
平安证券4月24日发布研报称，给予京新药业（002020.SZ）推荐评级。评级理由主要包括：1）公司24Q1收入端恢复较快增长，利润端重回长期增长轨道；2）成品药销售架构调整初见成效，产品盈利能力逐步优化；3）公司在手现金充裕，多条精神神经在研管线持续推进。（每日经济新闻）
Ping An Securities released a research report on April 24 stating that it gave Jingxin Pharmaceutical (002020.SZ) a recommended rating. The main reasons for the rating include: 1) the company's 24Q1 revenue side resumed relatively rapid growth, and the pr
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.